OSN SuperSite: Get the Whole Story, every day.
Search the OSN SuperSite   Login to OSN SuperSite
ASCsCataract surgeryCornea/External diseaseGlaucomaNeuro-sciencesOculoplasticsOphthalmic businessOptics/Contact lensesPediatrics/StrabismusPractice managementRefractive surgeryRegulatory/Legislative affairsRetina/Vitreous Podcasts
Subscribe Order Article Reprints Classified Marketplace Submit a Manuscript Meet the Editorial Boards Advertising Information Editorial Policies Buy a Book About SLACK Inc. Contact Us

Sign up for the Newswire

Regulatory/Legislative Print This Page
Send This Page To A Friend

OSN SuperSite Breaking News 11/11/2005

FDA approves Flomax labeling change

The labeling for a drug used to treat enlarged prostate will be altered to reflect information recently described regarding intraoperative floppy iris syndrome, a condition that occurs during cataract surgery in men who have taken the drug.

The approval of the labeling change for Flomax (tamsulosin HCl, Boehringer Ingelheim) was announced in a letter from the Food and Drug Administration to the manufacturer.

Flomax is an antagonist of alpha-1a adrenoceptors in the prostate, according to prescribing information for the drug. It is by the FDA approved for the treatment of benign prostatic hyperplasia, a condition affecting only men.

As reported first on the OSN SuperSite, David F. Chang, MD, and John R. Campbell, MD, found that current or previous use of Flomax may induce intraoperative floppy iris syndrome (IFIS) in patients undergoing cataract surgery. In a review of cataract patients, the researchers found a 2.3% incidence of IFIS, and 95% of those with the syndrome had a history of Flomax use, Dr. Chang said at that time. If a patient stops using tamsulosin 1 or 2 weeks before surgery, the risk of IFIS is reduced but not prevented, he said.

As a result of Drs. Chang and Campbell’s findings, Boehringer Ingelheim will include information about the syndrome in its Flomax labeling under general precautions. According to information submitted to the FDA, Boehringer Ingelheim will include the statement: “The patient’s ophthalmologist should be prepared for possible modifications to their surgical technique, such as the utilization of iris hooks, iris dilator rings or viscoelastic substances. The benefit of stopping alpha-1 blocker therapy prior to cataract surgery has not been established.”

· U.K. considering allowing optometrists to prescribe some ocular drugs
 OSN SuperSite Breaking News 8/4/2006

· Reimbursement, enforcement are key issues for ophthalmologists in 2006

· Washington Update

Print this page Send this article to a colleague Order article reprints    Submit a comment